Advanced Search

Journal of Traditional Chinese Medicine >

2023 , Vol. 43 >Issue 5: 876 - 886

DOI: https://doi.org/10.19852/j.cnki.jtcm.20230802.004

Active compounds of Caodoukou (Semen Alpinia Katsumadai) inhibit the migration, invasion and metastasis of human pancreatic cancer cells by targeting phosphoinosmde-3-kinase/ protein kinase B/mammalian target of rapamycin pathway

  • Xiaohui YANG ,
  • Jian WANG ,
  • Li CHENG ,
  • Yuxi ZHANG ,
  • Jianlin HUANG ,
  • Minghua LIU
Expand
  • 1 Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou 646000, China
    2 Department of Pharmacy, Luzhou Naxi District People's Hospital, Luzhou 646000, China
    3 Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou 646000, China

Received date: 2022-09-16

  Accepted date: 2022-12-19

  Online published: 2023-08-02

Supported by

Sichuan Science and Technology program: Study on the Molecular Mechanism and Reversal Strategy of Drug Resistance in “T + A” Therapy for Liver Cancer(2022YSF0625);Joint Project from Luzhou city and Southwest Medical University: Study on Preparation and Anti-colon Cancer Activity of PEG-PLGA Nanoparticles from Active Fraction of Clove(20ykdhz0008);Grants from National Natural Science Foundation of China: Study on the Interaction between Granulin A and ENO1 and Its Molecular Mechanism of Inhibiting Tumor Growth and Metastasis(81773776)

Fold

Abstract

OBJECTIVE: To detect the effects of active compounds of Caodoukou (Semen Alpinia Katsumadai) (ACAK) on the proliferation, migration and invasion of pancreatic cancer, and explain the possible molecular mechanism of ACAK interacting with these processes.
METHODS: Cell counting kit-8 method, cell scratch repair experiment, Transwell migration and invasion experiment, immunohistochemistry, western blot assay and real-time polymerase chain reaction experiment were used to evaluate the effect of ACAK on the proliferation, migration and invasion of pancreatic cancer cells. The levels of active molecules involved in the phosphoinosmde-3-kinase (PI3K)/Akt/the mammalian target of rapamycin (mTOR) signal transduction were detected by Western blot assay. In addition, the function of ACAK in vivo was evaluated by xenotransplantation tumor model in nude mice.
RESULTS: The inhibitory effect of ACAK on the proliferation of pancreatic cancer cells showed certain time-dose dependence. The results of scratch repair test, Transwell test, Western blotting and real time polymerase chain reaction assay showed that ACAK could inhibit the migration and invasion of pancreatic cancer cells in vitro. In addition, the regulatory effect of ACAK on epithelial-mesenchymal transition (EMT) is partly attributed to PI3K/Akt/mTOR signaling pathway. The experimental results in vivo showed that ACAK regulated the development of pancreatic cancer.
CONCLUSIONS: ACAK can partly inhibit the activity of EMT and matrix metallopeptidases by down-regulating the downstream proteins of PI3K/Akt/mTOR signal pathway, thus inhibiting the ability of migration and invasion of pancreatic cancer.

Key words： pancreatic neoplasms; PI3K; TOR serine-threonine kinases; Signal transduction; migration and invasion; active compounds; Caodoukou (Semen Alpinia Katsumadai)

Cite this article

Xiaohui YANG , Jian WANG , Li CHENG , Yuxi ZHANG , Jianlin HUANG , Minghua LIU . Active compounds of Caodoukou (Semen Alpinia Katsumadai) inhibit the migration, invasion and metastasis of human pancreatic cancer cells by targeting phosphoinosmde-3-kinase/ protein kinase B/mammalian target of rapamycin pathway[J]. Journal of Traditional Chinese Medicine, 2023 , 43(5) : 876 -886 . DOI: 10.19852/j.cnki.jtcm.20230802.004

References

1. Ferlay J, Colombet M, Soerjomataram I, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer 2018; 103: 356-87.
2. Liu X, Li T, Huang X, et al. DEPDC1B promotes migration and invasion in pancreatic ductal adenocarcinoma by activating the Akt/GSK3β/Snail pathway. Oncol Lett 2020; 20: 1.
3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020; 70: 7-30.
4. Cavallaro U, Christofori G. Multitasking in tumor progression: signaling functions of cell adhesion molecules. Ann NY Acad Sci 2004; 1014: 58-66.
5. Cao X, He Q. Anti-tumor activities of bioactive phytochemicals in Sophora flavescens for breast cancer. Cancer Manag Res 2020; 12: 1457-67.
6. Qi F, Zhao L, Zhou A, et al. The advantages of using Traditional Chinese Medicine as an adjunctive therapy in the whole course of cancer treatment instead of only terminal stage of cancer. Biosci Trends 2015; 9: 16-34.
7. Lee SE, Shin HT, Hwang HJ, Kim JH. Antioxidant activity of extracts from Alpinia katsumadai seed. Phytother Res 2003; 17: 1041-7.
8. Li H, Park JH, Lee JC, et al. Neuroprotective effects of Alpinia katsumadai against experimental ischemic damage via control of oxidative stress. Pharm Biol 2013; 51: 197-205.
9. Tan Y, Zheng C. Effects of Alpinetin on intestinal barrier function, inflammation and oxidative stress in dextran sulfate sodium-induced ulcerative colitis mice. Am J Med Sci 2018; 355: 377-86.
10. Liu Y, Wang K, Feng Q, et al. Alpinetin attenuates persistent inflammation, immune suppression, and catabolism syndrome in a septic mouse model. J Immunol Res 2021; 2021: 9998517.
11. Wang CC, Lu JW, Peng YJ, et al. Ameliorative effects of Cardamonin on monosodium urate-induced gouty arthritis through inhibiting NLRP 3 inflammasome iediation. Medicina (Kaunas, Lithuania) 2021; 57.
12. Wang XQ, Yang XJ, Li JS. Studies on chemical constituents of alpinia katsumadai. Zhong Yao Cai 2008; 31: 853-5.
13. Klan?nik A, Gr?blacher B, Kova? J, Bucar F, Mo?ina SS. Anti-Campylobacter and resistance-modifying activity of Alpinia katsumadai seed extracts. J Appl Microbiol 2012; 113: 1249-62.
14. Zhang T, Guo S, Zhu X, Qiu J, Deng G, Qiu C. Alpinetin inhibits breast cancer growth by ROS/NF-κB/HIF-1α axis. J Cell Mol Med 2020; 24: 8430-40.
15. Cheng Y, Dai C, Zhang J. SIRT3-SOD2-ROS pathway is involved in linalool-induced glioma cell apoptotic death. Acta Biochim Pol 2017; 64: 343-50.
16. Kim YJ, Kang KS, Choi KC, Ko H. Cardamonin induces autophagy and an antiproliferative effect through JNK activation in human colorectal carcinoma HCT116 cells. Bioorg Med Chem Lett 2015; 25: 2559-64.
17. Lim W, Park S, Bazer FW, Song G. Naringenin-induced apoptotic cell death in prostate cancer cells is mediated via the PI3K/AKT and MAPK signaling pathways. J Cell Biochem 2017; 118: 1118-31.
18. Wang HX, Tang C. Galangin suppresses human laryngeal carcinoma via modulation of caspase-3 and AKT signaling pathways. Oncol Rep 2017; 38: 703-14.
19. Chaffer CL, San Juan BP, Lim E, Weinberg RA. EMT, cell plasticity and metastasis. Cancer Metastasis Rev 2016; 35: 645-54.
20. Chen T, You Y, Jiang H, Wang ZZ. Epithelial-mesenchymal transition (EMT): a biological process in the development, stem cell differentiation, and tumorigenesis. J Cell Physiol 2017; 232: 3261-72.
21. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
22. Noronha C, Ribeiro AS, Taipa R, et al. Cadherin expression and EMT: a focus on gliomas. Biomedicines 2021; 9.
23. Zhang X, Liu G, Kang Y, Dong Z, Qian Q, Ma X. N-cadherin expression is associated with acquisition of EMT phenotype and with enhanced invasion in erlotinib-resistant lung cancer cell lines. PLoS One 2013; 8: e57692.
24. Jia H, Zhang Q, Liu F, Zhou D. Prognostic value of MMP-2 for patients with ovarian epithelial carcinoma: a systematic review and Meta-analysis. Arch Gynecol Obstet 2017; 295: 689-96.
25. Liu G, Jiang C, Li D, Wang R, Wang W. MiRNA-34a inhibits EGFR-signaling-dependent MMP7 activation in gastric cancer. Tumour Biol 2014; 35: 9801-6.
26. Zhang GJ, Zhao J, Jiang ML, Zhang LC. ING5 inhibits cell proliferation and invasion in esophageal squamous cell carcinoma through regulation of the Akt/NF-κB/MMP-9 signaling pathway. Biochem Biophys Resh Commun 2018; 496: 387-93.
27. Fattahi S, Amjadi-Moheb F, Tabaripour R, Ashrafi GH, Akhavan-Niaki H. PI3K/AKT/mTOR signaling in gastric cancer: epigenetics and beyond. Life Sci 2020; 262: 118513.
28. Jin Y, Feng SJ, Qiu S, Shao N, Zheng JH. LncRNA MALAT1 promotes proliferation and metastasis in epithelial ovarian cancer via the PI3K-AKT pathway. Eur Rev Med Pharmacol Sci 2017; 21: 3176-84.
29. Zhang L, Liang H, Xin Y. Cucurbitacin E inhibits esophageal carcinoma cell proliferation, migration, and invasion by suppressing Rac1 expression through PI3K/AKT/mTOR pathway. Anticancer Drugs 2020; 31: 847-55.
30. Song L, Zhang H, Hu M, et al. Sinomenine inhibits hypoxia induced breast cancer side population cells metastasis by PI3K/Akt/mTOR pathway. Bioorg Med Chem 2021; 31: 115986.
31. Yang N, Hui L, Wang Y, Yang H, Jiang X. SOX2 promotes the migration and invasion of laryngeal cancer cells by induction of MMP-2 via the PI3K/Akt/mTOR pathway. Oncol Rep 2014; 31: 2651-9.
32. Liu M, Zhao G, Zhang D, et al. Active fraction of clove induces apoptosis via PI3K/Akt/mTOR-mediated autophagy in human colorectal cancer HCT-116 cells. Int J Oncol 2018; 53: 1363-73.
33. Li C, Xu H, Chen X, et al. Aqueous extract of clove inhibits tumor growth by inducing autophagy through AMPK/ULK pathway. Phytother Res 2019; 33: 1794-804.
34. Wu N, Zhang C, Wang C, et al. Zinc-doped copper oxide nanocomposites reverse temozolomide resistance in glioblastoma by inhibiting AKT and ERK1/2. Nanomedicine (London, England) 2018; 13: 1303-18.
35. Xu B, Guo M, Ma L, et al. Mere15, a novel polypeptide from Meretrix meretrix, inhibits proliferation and metastasis of human non-small cell lung cancer cells through regulating the PI3K/Akt/mTOR signaling pathway. Neoplasma 2021; 68: 1181-89.
36. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983; 16: 109-10.
37. Polivka JR, Janku F. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol Ther 2014; 142: 164-75.
38. Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR signaling in cancer. Front Oncol 2014; 4: 64.
39. Hong C, Lishan W, Peng X, et al. Hsa_circ_0074298 promotes pancreatic cancer progression and resistance to gemcitabine by sponging miR-519 to target SMOC. J Cancer 2022; 13: 34-50.
40. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med 2013; 19: 1423-37.
41. Tang B, Du J, Wang J, et al. Alpinetin suppresses proliferation of human hepatoma cells by the activation of MKK7 and elevates sensitization to cis-diammined dichloridoplatium. Oncol Rep 2012; 27: 1090-6.
42. Shrivastava S, Jeengar M, Thummuri D, et al. Cardamonin, a chalcone, inhibits human triple negative breast cancer cell invasiveness by downregulation of Wnt/β-catenin signaling cascades and reversal of epithelial-mesenchymal transition. BioFactors (Oxford, England) 2017; 43: 152-69.
43. Niu PG, Zhang YX, Shi DH, Liu Y, Chen YY, Deng J. Cardamonin inhibits metastasis of Lewis lung carcinoma cells by decreasing mTOR activity. PLoS One 2015; 10: e0127778.
44. Gobin E, Bagwell K, Wagner J, et al. A pan-cancer perspective of matrix metalloproteases (MMP) gene expression profile and their diagnostic/prognostic potential. BMC Cancer 2019; 19: 581.
45. Huang H. Matrix metalloproteinase-9 (MMP-9) as a cancer biomarker and MMP-9 Biosensors: recent advances. Sensors (Basel) 2018; 18.
46. Kesh K, Subramanian L, Ghosh N, et al. A/G promoter polymorphism with gastric cancer risk: Influence of nicotine in differential allele-specific transcription via increased phosphorylation of CREB. J Biol Chem 2015; 290: 14391-406.
47. Ichimaru Y, Sano M, Kajiwara I, et al. Indirubin 3'-Oxime inhibits migration, invasion, and metastasis in vivo in mice bearing spontaneously occurring pancreatic cancer via blocking the RAF/ERK, AKT, and SAPK/JNK pathways. Transl Oncol 2019; 12: 1574-82.
48. Yang H, Dai G, Wang S, et al. Inhibition of the proliferation, migration, and invasion of human breast cancer cells by leucine aminopeptidase 3 inhibitors derived from natural marine products. Anticancer Drugs 2020; 31: 60-6.
49. Zhou P, Li XP, Jiang R, et al. Evodiamine inhibits migration and invasion by Sirt1-mediated post-translational modulations in colorectal cancer. Anticancer Drugs 2019; 30: 611-7.
50. Baselga J, Cortés J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366: 109-19.
51. Celia-Terrassa T, Meca-Cortes O, Mateo F, et al. Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells. J Clin Invest 2012; 122: 1849-68.
52. Chaw SY, Abdul Majeed A, Dalley AJ, Chan A, Stein S, Farah CS. Epithelial to mesenchymal transition (EMT) biomarkers--E-cadherin, beta-catenin, APC and Vimentin--in oral squamous cell carcinogenesis and transformation. Oral Oncol 2012; 48: 997-1006.
53. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 2006; 7: 131-42.
54. Zhang X, Liu G, Kang Y, Dong Z, Qian Q, Ma X. N-cadherin expression is associated with acquisition of EMT phenotype and with enhanced invasion in erlotinib-resistant lung cancer cell lines. PLoS One 2013; 8.
55. Brouxhon SM, Kyrkanides S, Teng X, et al. Soluble E-cadherin: a critical oncogene modulating receptor tyrosine kinases, MAPK and PI3K/Akt/mTOR signaling. Oncogene 2014; 33: 225-35.
56. Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006; 22: 159-68.
57. Ma Z, Lou S, Jiang Z. PHLDA2 regulates EMT and autophagy in colorectal cancer via the PI3K/AKT signaling pathway. Aging (Albany NY) 2020; 12: 7985-8000.
58. Wei R, Xiao Y, Song Y, Yuan H, Luo J, Xu W. FAT4 regulates the EMT and autophagy in colorectal cancer cells in part via the PI3K-AKT signaling axis. J Exp Clin Cancer Res 2019; 38: 112.
59. Xu W, Yu M, Qin J, Luo Y, Zhong M. LACTB regulates PIK3R3 to promote autophagy and inhibit EMT and proliferation through the PI3K/AKT/mTOR signaling pathway in colorectal cancer. Cancer Manag Res 2020; 12: 5181-200.
Options
Outlines

/

〈 〉